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Pancreatic cancer, the fifth leading cause of death from cancer
in the USA, is expected to cause nearly 30 000 deaths in 1998
(Landis et al, 1998). Despite the high mortality attributable to
pancreatic cancer, its aetiology is poorly understood. Cigarette
smoking is the only generally accepted risk factor, but explains
only about 25% of the disease (Silverman et al, 1994). Several
medical conditions have been reported to be associated with risk,
but results have been inconsistent across studies. Most persuasive
is the risk associated with diabetes mellitus (Everhart and Wright,
1995), with more limited evidence suggesting excess risk for gall-
bladder disease or cholecystectomy, chronic calcifying pancre-
atitis and ulcer or gastrectomy (Anderson et al, 1996). A history of
pancreatic cancer among first-degree relatives also has been
associated with elevated risk, while protective effects have been
reported for asthma and other allergies (Anderson et al, 1996). The
lack of consistency of results pertaining to pre-existing medical
conditions may be due to misclassification of information because of
the predominance of next-of-kin interviews in case-control studies of
pancreatic cancer. The rapidly fatal course of this cancer has made it
difficult to conduct case-control studies based exclusively on direct
interviews with the subjects in a population-based setting.
Our purpose was to conduct a large population-based case-
control study based on direct interviews and to evaluate medical
conditions/interventions and family history of cancer as risk
factors for pancreatic cancer.
MATERIALS AND METHODS
We conducted a population-based case-control study of malignan-
cies that occur excessively in blacks (i.e. cancers of the pancreas,
prostate, oesophagus and multiple myeloma) in three areas of the
USA. One general population control group was the source of
controls for all four types of cancer.
The case series in this analysis included all cases of carcinoma
of the pancreas (International Classification of Diseases for
Oncology code = 157) first diagnosed from August 1986 to April
1989 among 30- to 79-year-old residents of geographic areas
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covered by population-based cancer registries located in Atlanta
(DeKalb and Fulton counties), Detroit (Macomb, Oakland and
Wayne counties) and New Jersey (ten counties). To ensure both
the population-based nature of the case series and the complete-
ness of case ascertainment, all cases with reported pancreatic
cancer, regardless of the presence of tissue confirmation, were
initially included. Because about 15% of the cases lacked tissue
confirmation, an in-depth medical chart review was conducted to
determine the accuracy of diagnosis. Based on this review, 5.5% of
identified pancreatic cancer patients were excluded because they
were found to be ‘unlikely’ to have pancreatic cancer. Additional
details regarding the chart review are reported in a previous publi-
cation (Silverman et al, 1996).
Because of the rapidly fatal course of pancreatic cancer, death
was the main reason for non-participation. Despite our emphasis
on identifying and interviewing patients as quickly as possible
(median time from diagnosis to interview: 7 weeks), 471 of the
1153 patients initially identified for study died before the inter-
view could be conducted. Of the 682 living cases identified for
study, 526 (77%) were interviewed.
To evaluate the comparability of those who died to those who
lived long enough to be interviewed, we interviewed next of kin of
a sample of 325 deceased cases. The next-of-kin interview
included only broad categorical questions that next-of-kin respon-
dents have been shown to answer reliably (McLaughlin et al,
1990; Gavalda et al, 1995). For most questions, the pattern of
responses from next of kin of deceased cases was similar to that
for personally interviewed cases, including responses to questions
on ‘ever smoked cigarettes’, ‘ever drank coffee regularly’, ‘ever
drank alcohol regularly’ and ‘ever having been told by a physician
that they had a specified medical condition/intervention’. For
medical conditions/interventions, the percentages of next of kin
and directly interviewed respondents who reported the case as
having the following condition/intervention were: diabetes
mellitus (19% and 18% respectively), cholecystectomy (17% and
11% respectively), ulcer (14% and 16% respectively), asthma (9%
and 6% respectively), hay fever (19% and 12% respectively) and
eczema (7% and 5% respectively). These data suggest that inter-
viewed cases were probably representative of the total case series
with respect to most medical conditions/interventions. For chole-
cystectomy, asthma and hay fever, however, next of kin reported
higher percentages than directly interviewed subjects. Possible
under-reporting of such conditions/interventions by interviewed
cases may have resulted in underestimation of the risks for these
conditions/interventions.
The control series was drawn from the general population of the
study areas, frequency matching controls to the expected age-race-
gender distribution of cases of all four types of cancer combined in
each study area. Controls 30–64 years old were selected by
random-digit dialing (Waksberg, 1978). Of the 17 746 households
telephoned, 86% provided a household census that served as the
sampling frame for selection of controls under age 65 years. Of the
1568 controls chosen from these households, we interviewed 1227
(78%). Controls aged 65–79 years consisted of a stratified random
sample drawn from the Health Care Financing Administration
rosters of the population age 65 or older in each study area. Of the
1232 older controls selected, we interviewed 926 (75%).
Subjects were usually interviewed at home by interviewers who
were not informed of either the case or control status of the subject
or the hypotheses under study. Prior to interview, written informed
consent to participate in the study was obtained from each subject.
The questionnaire was designed to elicit detailed information
on medical conditions/interventions, family history of cancer,
smoking habits, alcohol consumption, coffee and tea drinking,
nutritional/dietary factors, usual occupation, and socioeconomic
status. Subjects were also queried about their usual adult height
and weight, which was used to compute body mass index (BMI)
(kg m–2 for men, kg m–1.5 for women) (Micozzi et al, 1986). The
effects of nutritional/dietary factors, cigarette smoking and alcohol
drinking on pancreatic cancer risk in this study have been reported
in earlier publications (Silverman et al, 1994, 1995, 1998).
We queried subjects to obtain detailed information on the
following medical conditions and interventions: diabetes mellitus,
cholecystectomy, pancreatitis, ulcer, gastrectomy and allergies.
We obtained information on cholecystectomy, rather than
cholelithiasis, because we believed recall of cholecystectomy
would be more accurate than that of cholelithiasis. Subjects were
asked questions regarding their age at onset and duration of each
medical condition and their age at the time of each surgery. All
Table 1 Number of cases and controls and odds ratios for pancreatic
cancer according to history of diabetes mellitus, cholecystectomy and ulcer
Condition/Intervention No of cases No of controls ORa 95% CI
Diabetes mellitusb
Interval between onset and
diagnosis of cancer (years)
No diabetes 398 1846 1.0
0–1 4 13 1.3 0.4–4.0
2–4 18 56 1.4 0.7–2.4
5–9 22 54 1.7 1.0–2.9
³10 42 127 1.5 1.01–2.2
Ever treated with insulinc
No diabetes 398 1846 1.0
No 31 96 1.5 1.0–2.3
Yes 33 85 1.6 1.04–2.5
Duration of insulin treatment
(years)
No diabetes 398 1846 1.0
0–4 10 19 2.6 1.1–5.8
5–9 11 18 2.3 1.1–5.1
10–19 5 35 0.7 0.3–1.8
³20 3 12 0.9 0.2–3.3
Cholecystectomy
Interval between surgery and
diagnosis of cancer (years)
No cholecystectomy 345 1941 1.0
0–1 78 8 57.9 27.3–123.0
2–4 8 15 2.7 1.1–6.6
5–9 11 30 1.9 0.9–3.9
10–19 14 50 1.4 0.7–2.6
³20 21 47 1.7 1.0–3.0
Ulcer
History of ulcerd
No 407 1821 1.0
Yes 76 277 1.2 0.9–1.6
Ulcer treated by gastrectomyd
No ulcer 407 1821 1.0
Ulcer without gastrectomy 60 233 1.2 0.9–1.6
Ulcer with gastrectomy 10 39 1.2 0.6–2.5
aOdds ratios adjusted for age at diagnosis/interview, race, gender, area,
cigarette smoking, alcohol consumption, body mass index and calories from
food. bExcludes three controls diagnosed with diabetes mellitus before age
20 years. cExcludes subjects diagnosed with diabetes mellitus less than 5
years prior to the diagnosis of pancreatic cancer. dOdds ratios also adjusted
for income (men) and marital status (women).1832 DT Silverman et al
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analyses pertaining to diabetes mellitus were restricted to subjects
with adult onset diabetes because only three subjects (zero cases,
three controls) reported onset of diabetes before age 20. We also
obtained detailed information on the use of insulin and other drugs
to treat diabetes mellitus. With regard to allergies, we elicited
detailed information on all allergies, including hay fever, asthma,
eczema, allergies to insect bites, food, animals, drugs,
dusts/mould, household products and cosmetics. Medications used
to treat asthma, including the use of bronchodilators and steroids,
also were obtained. Only seven cases and ten controls reported a
hospitalization for pancreatitis, prohibiting any detailed analysis of
this potential risk factor.
With regard to family history of cancer, subjects were asked
whether any first-degree blood relative ever had cancer, and if so,
to specify the type of neoplasm. We did not, however, enumerate
all members of the immediate family. Risk associated with family
history of cancer in the children of subjects was not included
because the number of subjects reporting children with cancer was
small.
The effects of medical conditions/interventions and family history
of cancer on pancreatic cancer risk were quantified by the odds ratio
(OR). ORs and 95% confidence intervals (CIs) were estimated by
unconditional logistic regression analysis (Breslow and Day, 1980;
Dixon et al, 1990). Statistical models included terms for exposure
(i.e. diabetes mellitus, cholecystectomy, ulcer, gastrectomy, or aller-
gies), the matching factors (i.e. age at diagnosis/interview, race,
gender and study area), as well as terms for potential confounding
variable (i.e. cigarette smoking, alcohol consumption, body mass
index, caloric intake, income (men) and marital status (women)).
For family history of cancer, only the matching factors were
included in the models because additional adjustment for smoking,
alcohol consumption and other potential confounding factors had
little or no impact on estimates of risk. To test for trend, the exposure
variable was treated as continuous by entering the median value for
each level of the categorical variable among the controls.
Interviewed subjects were excluded from analysis for the
following reasons: unlikely diagnosis of pancreatic cancer (16
cases), presence of islet cell carcinoma (ten cases), no medical
record available for review (six cases), unsatisfactory interview
(one case and seven controls), and missing data (nine cases and 47
controls). Thus, the analysis of medical conditions/interventions
was based on first-person interviews with 484 ‘likely’ cases with a




Table 1 shows risk of pancreatic cancer by length of the interval
between diagnosis of diabetes and cancer. A significant positive
trend in risk with increasing years prior to diagnosis of cancer was
apparent (P = 0.016). Risk was slightly elevated for subjects with
onset of diabetes within 1 year of diagnosis of cancer (OR = 1.3;
CI = 0.4–4.0). For subjects with longer intervals, risks were signif-
icantly increased, with ORs of 1.7 (CI = 1.01–2.9) and 1.5 (CI =
1.01–2.2) for those with onset of diabetes within 5–9 years and 10
or more years before the diagnosis of cancer respectively.
Treatment for diabetes was unrelated to pancreatic cancer risk.
Compared to non-diabetics, diabetics who were treated with
insulin had an OR of 1.6 (CI = 1.04–2.5), while those who were
not treated with insulin had an OR of 1.5 (CI = 1.0–2.3). There was
no trend in risk with increased duration of insulin use (Table 1).
Diabetics treated with oral medications (OR = 1.4; CI = 0.8–2.6)
had risks similar to those who did not (OR = 1.5, CI = 1.1–2.2),
while those with special dietary restrictions had a non-significantly
higher risk than those without such restrictions (OR = 1.7 and 1.4
respectively). There was only one case and six controls with
diabetes who did not have any form of treatment.
Family history of diabetes did not appear to be related to risk of
pancreatic cancer. Compared to subjects with no family history,
diabetics with a positive family history had an OR of 0.8, while
non-diabetics with a positive family history had an OR of 1.0.
Because obesity, an important risk factor for diabetes, has been
linked to pancreatic cancer risk in our study (Silverman et al,
1998) as well as others (Friedman and van den Eeden, 1993;
Moller et al, 1994; Shibata et al, 1994; Ji et al, 1996), we cross-
Table 2 Odds ratios for pancreatic cancer according to history of diabetes
mellitus and body mass index
Body Mass Indexa,b
History of diabetes 1 2 3 4
No
OR 1.0c 1.2 1.4 1.6
95% CI – 0.8–1.6 1.1–2.0 1.2–2.2
No. cases/No. controls 90/503 100/499 112/462 118/451
Yesd
OR 2.7 1.7 1.8 2.2
95% CI 1.3–6.0 0.7–3.9 1.0–3.4 1.3–3.7
No. cases/No. controls 11/22 8/28 16/55 29/76
aBMI = weight height2 for men; BMI = weight height1.5 for women. bQuartile
cut-points for BMI (based on controls) – men: 17.4–23.1; 23.2–25.1;
25.2–27.2; >27.2 (kg/m–2); women: 20.5–27.5; 27.6–30.2; 30.3–34.2; ³34.4
(kg/m–1.5). cOdds ratios adjusted for age at diagnosis/interview, race, gender,
area, cigarette smoking, alcohol consumption and calories from food.
dExcludes subjects diagnosed with diabetes less than 5 years prior to
diagnosis of pancreatic cancer.
Table 3 Odds ratios for pancreatic cancer according to history of
cholecystectomy and body mass index
Body Mass Indexa,b
History of cholecystectomy 1 2 3 4
No
OR 1.0c 1.0 1.1 1.3
95% CI – 0.7–1.4 0.8–1.6 0.9–1.8
No cases/No. controls 84/494 83/497 83/476 95/474
Yesd
OR 0.8 1.9 1.7 2.6
95% CI 0.3–2.4 0.8–4.5 0.8–3.5 1.5–4.6
No cases/No. controls 4/26 8/22 12/34 22/45
a BMI = weight height2 for men; BMI = weight height1.5 for women. bQuartile
cut-points for BMI (based on controls) – men: 17.4–23.1; 23.2–25.1;
25.2–27.2; >27.2 (kg/m–2); women: 20.5–27.5; 27.6–30.2; 30.3–34.2; ³34.4
(kg/m–1.5). cOdds ratios adjusted for age at diagnosis/interview, race, gender,
area, cigarette smoking, alcohol consumption and calories from food. 
dExcludes subjects who received a cholecystectomy less then 5 years prior
to the diagnosis of pancreatic cancer.Medical conditions and pancreatic cancer risk 1833
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classified risk simultaneously by history of diabetes and BMI in
Table 2. Within each level of BMI, diabetics had a higher risk than
non-diabetics. In addition, a significant positive trend in risk with
increasing BMI was apparent for non-diabetics (P = 0.02), but not
for diabetics. These trends, however, were not significantly
different from each other (P > 0.05).
Cholecystectomy
Table 1 presents risk following cholecystectomy according to the
length of the interval to diagnosis of pancreatic cancer. Within 1
year prior to the cancer diagnosis, the risk associated with chole-
cystectomy was extremely high (OR = 57.9, CI 27.3–123.0).
Although much diminished, risk remained elevated with increasing
years prior to the diagnosis of cancer. Subjects who had a chole-
cystectomy 20 or more years prior to the cancer diagnosis had an
OR of 1.7 (CI = 1.0–3.0).
Because obesity is a risk factor for cholelithiasis, we cross-classi-
fied pancreatic cancer risk by history of cholecystectomy and BMI
(Table 3). Within each level of BMI except the first quartile, subjects
with cholecystectomy experienced an excess risk compared to those
who did not have this procedure. Cholecystectomy also appeared to
modify the BMI effect. The risk gradient associated with BMI was
stronger among subjects with cholecystectomy than among those
without, but these gradients were not significantly different from
each other (P > 0.05). Risk for subjects in the top BMI quartile was
higher for those with a cholecystectomy (OR = 2.6, CI = 1.5–4.6)
than for those without (OR = 1.3, CI = 0.9–1.8).
Ulcer/gastrectomy
Little or no excess risk was associated with having had a duodenal
or gastric ulcer (OR = 1.2, CI = 0.9–1.6) (Table 1). Subjects treated
by full or partial gastrectomy had the same risk (OR = 1.2) as those
without gastrectomy (OR = 1.2).
Allergies
Table 4 shows risk of pancreatic cancer by history of allergies.
Subjects with a history of any allergic condition had a significantly
reduced risk (OR = 0.7, CI = 0.5–0.9). This overall risk reduction,
however, was mainly due to a decreased risk among subjects with
a history of hay fever, although non-significant decreased risks
also were seen among subjects with allergies to animals or to dust
or moulds. No protective effects were associated with a history of
asthma, eczema or allergy to insect bites/stings. Increased risks
were observed for subjects with allergies to drugs (OR = 1.6,
CI = 1.2–2.1) and for those with allergies to household products
(OR = 1.7, CI = 0.9–3.1).
Compared to subjects without allergies, those who had allergy
shots had risks similar to those who never had allergy shots, with
no consistent trend in risk with increasing number of shots (Table
5). No significantly decreased risks were observed among asth-
matics who used bronchodilators or steroids or both compared to
subjects without allergies.
Family history of cancer
Table 6 gives risk of pancreatic cancer by history of cancer among
first-degree relatives. A significant 30% increased risk was associ-
ated with a family history of any cancer. Subjects with a family
Table 4 Number of cases and controls and odds ratios for pancreatic
cancer according to history of hay fever, asthma and other allergic conditions
Allergic condition No. of cases No. of controls ORa 95% CI
No allergic condition 277 1180 1.0
Any allergic condition 76 488 0.7 0.5–0.9
Hay fever 58 403 0.6 0.5–0.9
Asthma 29 117 1.0 0.6–1.5
Eczema 23 78 1.1 0.7–1.9
Animal allergy 6 54 0.5 0.2–1.1
Insect bite/sting allergy 37 181 0.8 0.6–1.2
Dust or mold allergy 13 98 0.6 0.3–1.1
Drug allergy 81 215 1.4 1.0–1.9
Household products allergy 15 36 1.5 0.8–2.9
aOdds ratios adjusted for age at diagnosis/interview, race, gender, area,
cigarette smoking, alcohol consumption, body mass index and calories from
food. CI, confidence intervals.
Table 5 Number of cases and controls and odds ratios for pancreatic
cancer according to treatment for allergic conditions
Treatment No. of cases No. of controls ORa 95% CI
Allergy shots
No allergic conditions 277 1180 1.0
Never allergy shots 148 703 0.9 0.7–1.1
Ever allergy shots 23 124 0.8 0.5–1.3
Number of allergy shots
0 425 1883 1.0
<10 8 37 1.0 0.5–2.2
10–49 6 35 0.9 0.4–2.2
50–99 1 13 0.4 0.1–2.8
³100 8 39 0.9 0.4–2.0
Asthma treatment
No bronchodilators or steroids 11 41 1.0
Bronchodilators, no steroids 7 43 0.7 0.2–2.3
Steroids, no bronchodilators 4 8 2.5 0.5–13.9
Bronchodilators and steroids 5 14 1.1 0.2–4.5
aOdds ratios adjusted for age at diagnosis/interview, race, gender, cigarette
smoking, alcohol consumption, body mass index and calories from food. CI,
confidence intervals.
Table 6 Number of cases and controls and odds ratios for pancreatic
cancer according to family history of cancera
Site of cancer
in first-degree relatives No. of cases No. of controls ORb 95% CI
All sites combined 218 784 1.3 1.1–1.6
Pancreas 23 31 3.2 1.8–5.6
Oesophagus 2 14 0.6 0.1–2.9
Stomach 27 120 0.9 0.6–1.4
Colon 36 91 1.7 1.1–2.5
Liver 12 37 1.4 0.7–2.7
Lung 30 111 1.1 0.7–1.7
Breast 40 128 1.3 0.9–1.9
Ovary 5 4 5.3 1.4–20.2
Endometrium 15 41 1.5 0.8–2.8
Prostate 11 49 1.0 0.5–1.9
aExcludes 25 cases and 39 controls with missing information on family
history of cancer. bOdds ratios relative to a risk of 1.0 for subjects with no
family history of cancer, adjusted for age at diagnosis/interview, race, gender
and area. CI, confidence intervals.1834 DT Silverman et al
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history of pancreatic cancer had a significantly elevated risk
(OR = 3.2, CI = 1.8–5.6). This risk was higher for those with
pancreatic cancer in a sibling (OR = 3.6, CI = 1.5–8.7) than in a
parent (OR = 2.6, CI = 1.2–5.4). Family history of pancreatic
cancer was associated with a higher risk among long-term smokers
(i.e. smokers for 20 or more years) (OR = 5.3, CI = 2.1–13.4) than
non-smokers/short- and moderate-term smokers (i.e. smoked for
less than 20 years) (OR = 2.2, CI = 1.0–7.9), although the inter-
action between familial predisposition and smoking was not statis-
tically significant (P > 0.05). Risk associated with familial
occurrence did not vary by age at diagnosis/interview of the
subject. In fact, point estimates for subjects aged 45–64 years and
those aged 65 years or older were identical (OR = 3.3), with CIs of
1.4–7.8 and 1.5–7.2 respectively. There were no cases and two
controls under age 45 at diagnosis/interview who reported pan-
creatic cancer in a first-degree relative.
With regard to family history of other cancers (Table 6), risk of
pancreatic cancer was significantly elevated for subjects with a
family history of cancers of the colon (OR = 1.7) or ovary
(OR = 5.3), and non-significantly elevated for those with a family
history of cancers of the endometrium (OR = 1.5), breast
(OR = 1.3), or liver (OR = 1.4).
DISCUSSION
Our findings indicate that diabetes mellitus is a risk factor for
pancreatic cancer, as well as a potential consequence of pancreatic
cancer. In particular, subjects diagnosed with diabetes at least 10
years prior to the diagnosis of cancer had a significant 50%
increased risk, while a non-significant 30% increased risk was
seen for subjects whose diabetes was detected within 1 year of the
diagnosis of cancer.
The association between diabetes mellitus and pancreatic cancer
has been evaluated in more than 30 studies (Green and Jensen, 1985;
Chow et al, 1995; Everhart and Wright, 1995; Wideroff et al, 1997;
Calle et al, 1998), with most indicating a positive relationship. The
critical question has been whether diabetes is a true aetiologic factor
or a consequence of pancreatic cancer during a prediagnostic stage.
When diabetes arises around the time of cancer diagnosis, it is
usually characterized by marked insulin resistance with hyperinsuli-
naemia that declines after tumour resection (Permert et al, 1994). In
1994, Permert and colleagues showed that, among pancreatic cancer
patients, those with diabetes have elevated plasma levels of islet
amyloid polypeptide (IAPP), a hormonal factor secreted by B-cells,
which may cause insulin resistance and contribute to diabetes in
these patients (Permert et al, 1994).
Our study and others indicate that diabetes is also a risk factor
for pancreatic cancer. In 1995, Everhart and Wright reported
results of a meta-analysis of pancreatic cancer studies and found
that diabetics diagnosed at least 5 years prior to the diagnosis of
cancer had a relative risk (RR) of 2.0 (CI = 1.2–3.2). The pooled
estimate from the cohort studies (RR = 2.6) was higher than that
from the case-control studies (OR = 1.8). Our results are consistent
with the pooled estimate for case-control studies.
The mechanism by which long-standing diabetes causes pancre-
atic cancer is uncertain. One possibility is that the relation is medi-
ated by obesity, which is a risk factor for diabetes (Colditz et al,
1995) and pancreatic cancer in the present study (Silverman et al,
1998) as well as previous studies (Friedman and van den Eeden,
1993; Moller et al, 1994; Shibata et al, 1994; Ji et al, 1996). We
found, however, that diabetes was related to risk of pancreatic
cancer within each quartile of BMI, most notably in the lowest
BMI quartile (170% increased risk).
Another possible mechanism derives from experimental studies
indicating that exposure to insulin promotes growth in human
pancreatic cell lines (Fisher et al, 1996). Hyperinsulinaemia is
characteristic of both obesity and non-insulin-dependent diabetes
mellitus (NIDDM) (DeFronzo et al, 1997), and may play a key
role in pancreatic carcinogenesis (Everhart and Wright, 1995).
Among non-diabetics, resistance to insulin action typically
increases with increasing BMI, which results in hyperinsulin-
aemia. Among diabetics, insulin levels are not strongly correlated
with BMI, but depend mainly on the degree of impaired B-cell
function and hyperglycaemia. The role of hyperinsulinaemia in
pancreatic cancer risk is consistent with our finding that the
diabetes-related risk was not influenced by obesity, while the risk
associated with increasing BMI was seen only in non-diabetics. To
further test this hypothesis will require a large-scale cohort study
with repeated serum collections to determine if and when insulin
levels become elevated prior to the onset of pancreatic cancer.
A third possible mechanism is based on experimental observa-
tions that peripheral insulin resistance is associated with increased
cell turnover of the pancreatic islets, and stimulation of islet cell
proliferation enhances pancreatic carcinogenesis in Syrian
hamsters (Pour and Kazakoff, 1996), which is considered an excel-
lent animal model for human pancreatic carcinogenesis (Kazakoff
et al, 1996).
Lastly, the observed association between long-standing diabetes
and pancreatic cancer may be due to confounding by a correlated
variable. This explanation seems unlikely because the OR for
diabetes was adjusted for age at diagnosis/interview, race, gender,
geographic area, cigarette smoking, alcohol consumption, BMI
and calories from food. Adjustment for other potential
confounders had little or no impact. Moreover, the relation
between long-standing diabetes and pancreatic cancer has been
found in at least 20 previous studies conducted in a variety of
populations over time (Chow et al, 1995; Everhart and Wright,
1995; Wideroff et al, 1997), diminishing the likelihood that the
observed effect is due to confounding.
Another key finding of our study was the positive association
between cholecystectomy and pancreatic cancer risk. The 57-fold
increased risk for subjects with cholecystectomy within 1 year of
cancer diagnosis is probably an artifact resulting from either
surgery prompted by symptoms of pancreatic cancer or inaccurate
recall of patients regarding diagnostic work-up or treatment. Risk,
however, remained elevated with increasing years prior to the
diagnosis of malignancy, with a 70% excess risk among subjects
with cholecystectomy 20 or more years prior to diagnosis of
pancreatic cancer. According to our next-of-kin results (see
Materials and Methods), the true magnitude of this risk may, in
fact, have been underestimated. Our results suggest that chole-
cystectomy is a risk factor for pancreatic cancer, as well as a
consequence of the malignancy.
These findings are consistent with most studies of cholecyst-
ectomy/gallbladder disease and pancreatic cancer. Of at least 17
studies conducted to date, 11 have been positive (Wynder et al,
1973; La Vecchia et al, 1980; Lin and Kessler, 1981; Norell and
Ahlbom, 1986; Hyvarinen and Partanen, 1987; Cuzick and
Babiker, 1989; Kalapothaki et al, 1993; Shibata et al, 1994; Ekbom
et al, 1996; Johanson et al, 1996; Chow et al, 1998). Few studies,
however, have considered timing of the cholecystectomy/gall-
bladder disease in relation to pancreatic cancer. Of the 11 studiesMedical conditions and pancreatic cancer risk 1835
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indicating a positive association, only four demonstrated an
increased pancreatic cancer risk 5 or more years prior to the cancer
diagnosis (Norell and Ahlbom, 1986; Hyvarinen and Partanen,
1987; Shibata et al, 1994; Chow et al, 1998), while our study is the
first to show an increased risk for subjects with a cholecystectomy
at least 20 years prior to the cancer diagnosis, an interval too long
to be considered prodromal to pancreatic cancer. A causal relation
is further supported by experimental studies showing that chole-
cystectomy increases circulating levels of cholecystokinin (CCK),
which is a major regulator of pancreatic growth and enzyme secre-
tion (Warshaw and Fernandez-del Castillo, 1992), and a promoter
of pancreatic carcinogenesis in rodents (Howatson and Carter,
1985; Smith et al, 1990). Potential confounding by obesity, which
is a risk factor for cholelithiasis and pancreatic cancer, was ruled
out in our study.
We observed little or no excess risk associated with duodenal or
gastric ulcer or with gastrectomy as treatment for ulcer. Of 16
previous studies that have examined gastrectomy as a risk factor
for pancreatic cancer, ten reported a positive association (McLean-
Ross et al, 1982; Mack et al, 1986; Caygill et al, 1987; Offerhaus
et al, 1987; Mills et al, 1988; Farrow and Davis, 1990; Tersmette
et al, 1990; Eide et al, 1991; Mooller and Toftgaard, 1991; Bueno
de Mesquita et al, 1992), while six studies in addition to ours
found no association (Wynder et al, 1973; Maringhini et al, 1987;
La Vecchia et al, 1990; Jain et al, 1991; Kalapothaki et al, 1993;
Gullo et al, 1996). Of only four studies that examined history of
ulcer in relation to pancreatic cancer risk, none found an associa-
tion in accord with our findings (Mack et al, 1986; La Vecchia et
al, 1990; Jain et al, 1991; Bueno de Mesquita et al, 1992).
A protective effect for allergic conditions including asthma has
been reported in some studies of pancreatic cancer (Mack et al,
1986; Mills et al, 1988; Jain et al, 1991; Bueno de Mesquita et al,
1992; Kalapothaki et al, 1993; Dai et al, 1995), but our results are
consistent with three studies that showed little effect (Gold et al,
1985; Farrow and Davis, 1990; La Vecchia et al, 1990). Since
most case-control studies of pancreatic cancer have been based
primarily on interviews with next of kin, the reliability of detailed
information on allergic disorders may be questionable (Gavalda
et al, 1995). Although we observed reduced risks for some condi-
tions such as hay fever and allergies to animals and dust/moulds,
no protective effect was seen for other types of allergies, so the
findings may have been due to chance. In addition, the reduced
risk for hay fever may have been due to the possible underestima-
tion of the hay fever risk resulting from potential under-reporting
of hay fever by interviewed cases as previously indicated in the
Methods section.
The threefold risk associated with a family history of pancreatic
cancer in first-degree relatives resembles the risk estimates
reported in case-control studies in the USA (Falk et al, 1988),
Canada (Ghadirian et al, 1991) and Italy (Fernandez et al, 1994).
In addition, the risk of pancreatic cancer associated with familial
occurrence was highest among long-term cigarette smokers,
suggesting an interaction between smoking and genetic predispo-
sition. Subjects with a family history of pancreatic cancer who
smoked at least 20 years had a fivefold risk compared to a twofold
risk among non-smokers and those who smoked for shorter dura-
tions. It is possible, however, that the differential familial risks are
partly related to a tendency of smokers to have relatives who also
smoke rather than to genetic predisposition. This possibility seems
unlikely because there were no excesses associated with a family
history of other smoking-related sites such as lung cancer.
Alternatively, chance could not be reasonably excluded as an
explanation for the differential familial risks by smoking status.
The elevated risk of pancreatic cancer extended to subjects with
a family history of cancers of the colon (OR = 1.7), ovary (OR =
5.3), endometrium (OR = 1.5) and breast (OR = 1.3). These find-
ings are consistent with the constellation of tumours associated
with hereditary non-polyposis colon cancer (Lynch et al, 1985;
Lumadue et al, 1995). This study is the first to report elements of
the syndrome in a population-based study of pancreatic cancer,
suggesting that the syndrome may occur more frequently than
anticipated. In fact, 21% of cases compared to 13% of controls
reported a first-degree relative with at least one of the types of
cancer included in the syndrome, yielding a population attribut-
able risk of 8% for the syndrome. Because tumour types were not
confirmed in our study, these results need to be corroborated. The
excess risk associated with a family history of liver cancer (OR =
1.4) is particularly questionable since it probably includes many
more metastatic, rather than primary, liver cancers.
In summary, our population-based study indicates that diabetes
and cholecystectomy are independent risk factors, as well as
potential consequences of the malignancy, suggesting the role of
metabolic factors in pancreatic cancer and opportunities for
medical surveillance to detect early pancreatic cancer. We did not
confirm the increased risk associated with gastrectomy or protec-
tive effects of allergies that have been reported in some, though not
all, previous studies. The threefold risk of pancreatic cancer
among first-degree relatives of affected individuals is consistent
with previous studies, and the higher familial risk in smokers than
non-smokers suggests the possibility of a gene–environment inter-
action. An increased risk of pancreatic cancer also was associated
with a family history of colon, endometrium, ovary and breast
cancer, suggesting a possible link to hereditary non-polyposis
colon cancer.
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